Health Canada Approves of DENOZA™, a Denosumab Biosimilar
May 5, 2026
Apotex Inc., a Canadian based global pharmaceutical company announced that Health Canada has approved DENOZA™ (denosumab injection), a denosumab biosimilar, for its authorized indications.
These include the treatment of postmenopausal women with osteoporosis at high risk for fracture and the treatment of osteoporosis in men at high risk for fracture. DENOZA is also authorized for the remaining indications of the reference biologic.
Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones
July 7, 2026
Latest News Researchers Use Machine Learning To Better Predict Fractures Caused By Weak Bones July 7, 2026 Fragility fractures are a major and growing health burden, with significant personal and […]
INESSS in Quebec has issued a recommendation to transfer denosumab from the Exceptional Drugs section to the Regular section
June 23, 2026
Latest News INESSS in Quebec has issued a recommendation to transfer denosumab from the Exceptional Drugs section to the Regular section June 23, 2026 INESSS (the Institut national d’excellence en […]
Health Canada Approves of DENOZA™, a Denosumab Biosimilar
May 5, 2026
Latest News Health Canada Approves of DENOZA™, a Denosumab Biosimilar May 5, 2026 Apotex Inc., a Canadian based global pharmaceutical company announced that Health Canada has approved DENOZA™ (denosumab injection), […]
